A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
Latest Information Update: 27 May 2025
At a glance
- Drugs GSK-3862995B (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
Most Recent Events
- 27 May 2025 New trial record